Expression of the non-receptor tyrosine kinase FAK has been shown to correlate with aggressive disease stage in NSCLC [27] and inhibitors of FAK are effective at inhibiting tumor growth in various mouse xenograft models [23,24]. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.